ABAT vs AMPX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABAT and AMPX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABAT and AMPX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

American Battery Technology Company (ABAT), based in Reno, Nevada, operates a commercial-scale lithium-ion battery recycling facility designed to process roughly 20,000 metric tonnes of feedstock per year into battery-grade metals such as lithium, nickel, cobalt, and manganese. The company recovers these critical minerals from end-of-life batteries and manufacturing scrap, aiming to feed them back into the domestic battery supply chain. In fiscal 2026 (the year ended June 30, 2026) revenue rose about 407% to roughly $21.7 million as throughput more than quadrupled, and the company reported a non-GAAP adjusted gross profit of about $1.7 million versus a $6.2 million adjusted gross loss a year earlier (on a GAAP basis it still posted a gross loss of about $3.1 million), and it has announced plans for a second, larger recycling facility designed to handle around 100,000 metric tonnes of battery materials per year.

Full ABAT guide

Amprius Technologies develops and sells silicon-anode lithium-ion batteries that target higher energy density than conventional graphite-anode cells, meaning more energy in the same weight and volume. Its SiMaxx platform uses a proprietary 100% silicon-nanowire anode made in-house at its Fremont, California facility and is positioned for the most demanding high-performance uses, while its newer SiCore platform is a commercially available silicon-anode line, including a 450 Wh/kg cell, designed for near-term mass production. Higher energy density matters most where weight is critical, which is why Amprius concentrates on aviation, electric vertical takeoff and landing (eVTOL) aircraft, drones, defense, and electric vehicles. The company ships cells to a broad and growing base of customers and holds defense agreements such as a contract with the U.S. Defense Innovation Unit for NDAA-compliant advanced drone batteries.

Full AMPX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABAT drivers: Recycling ramp; Tonopah Flats lithium resource.
• AMPX drivers: Energy-density edge; Aviation, defense, and drone demand.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: ABAT is an early-commercial, pre-profit company whose biggest risk is execution: scaling recycling to consistent profitability and financing and building the Tonopah Flats lithium project are both unproven and capital-intensive. For AMPX, amprius is in an early commercial ramp and is not yet consistently profitable, so it depends on its cash balance and may need to raise capital, which can dilute shareholders.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABAT if you believe its drivers more; AMPX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABAT and AMPX guides.

ABAT. ABAT is a speculative, early-commercial company, so traditional valuation multiples do not apply: it is pre-profit, burning cash, and funding itself largely through equity issuance and government grants. At roughly 10 times trailing revenue and about 4.5 times its June cash balance, the market still values it on the potential of the recycling ramp and the Tonopah Flats project, and the 73% one-year decline shows how sensitive the price is to dilution, export policy, and battery-metal prices.

AMPX. Amprius is a speculative, ramp-stage company, so it cannot be valued on current earnings; the market prices it on the option value of future growth, at roughly 11 times trailing sales. Analysts expect a small loss in 2026 and about $0.10 of EPS in 2027 on revenue near $212 million, so the valuation leans on that ramp arriving on time. Cash, share count and market cap can move materially with capital raises, and the October 2026 shelf filing makes that more likely to come up.

Headline figures (approximate, October 2026 (fiscal year ended June 30, 2026)): ABAT shows revenue (fy2026) ~$21.7 million (up ~407% year over year); Q4 FY26 ~$8.2 million, gross profit ~$1.7 million adjusted (non-GAAP); GAAP gross loss ~$3.1 million, net loss (fy2026) ~$73.4 million (EPS ~-$0.58), net loss (q4 fy26) ~$20.0 million (EPS ~-$0.15 vs ~-$0.06 consensus); AMPX shows revenue (ttm) ~$109 million, revenue (q2 2026) ~$34.0 million (up ~126% year over year), revenue (fy2025) ~$73.0 million (up about 3x year over year), gross margin (ttm) ~22%.

ABAT and AMPX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABAT and AMPX exposure against your real portfolio. It is not an investment adviser.